Phase 2 Trial of Nab-paclitaxel Plus FOLFOX As First-line Therapy for Gastric Cancer

Share this content:
Researchers are evaluating the safety and efficacy of FOLFOX plus nab-paclitaxel as a first-line therapy for patients with advanced gastric cancer or adenocarcinoma of the gastroesophageal junction.
Researchers are evaluating the safety and efficacy of FOLFOX plus nab-paclitaxel as a first-line therapy for patients with advanced gastric cancer or adenocarcinoma of the gastroesophageal junction.

Title: A Phase II Study of FOLFOX Combined With Nab-Paclitaxel (FOLFOX-A) in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma. Big Ten Cancer Research Consortium: BTCRC-GI15-0151

Principal Investigators: Al Benson, MD, Northwestern University Feinberg School of Medicine

Description: For this open-label, phase 2 study, researchers are evaluating the safety and efficacy of FOLFOX plus nab-paclitaxel (FOLFOX-A) as a first-line therapy for patients with histologically confirmed advanced gastric cancer or adenocarcinoma of the gastroesophageal junction.

Patients with stage I and II disease will receive FOLFOX-A every 2 weeks for each 4 week cycle. Intravenous (IV) nab-paclitaxel will be administered over 30 minutes, followed by IV oxaliplatin and IV leucovorin over 2 hours, as well as IV 5-FU as continuous infusion over Days 1 and 2.

The primary outcome measure is the 2-year overall objective response rate. Secondary outcome measures include overall survival, progression-free survival, time to progression, best overall response rate, best disease control rate, and adverse events. All outcomes will be evaluated over 5 years.

The estimated enrollment is 39 patients.

For more study information, including exclusion and inclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT03283761.

Status: This study is open and recruiting patients as of October 26, 2017.

This study is sponsored by Al B. Benson, III, MD, in collaboration with Celgene Corporation and the Big Ten Cancer Research Consortium.

Reference

  1. Clinicaltrials.gov. FOLFOX-A in the treatment of metastatic or advanced unresectable gastric, gastro-esophageal junction adenocarcinoma. NCT03283761. https://clinicaltrials.gov/ct2/show/NCT03283761. Accessed October 26, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters